Skip to main content

Table 4 Absolute decline in DLCO from baseline over 12 months

From: Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials

  Placebo group Cyclophosphamide group
  Number of subjects Absolute decline in DLCO from baseline (%), mean (SD) p Value Number of subjects Absolute decline in DLCO from baseline (%), mean (SD) p Value
Visual maximum fibrosis score
 0–25 % 19 −1.6 (10.8) 0.62 13 −6.0 (9.2) 0.64
 26–100 % 29 −3.2 (10.9) 30 −4.7 (7.2)
Goh and Wells criteria, unadjusted stratification
 <20 % 22 −3.0 (11.5) 0.98 15 −6.9 (8.4) 0.30
 >20 % 25 −3.0 (9.9) 30 −4.3 (7.1)
Goh and Wells criteria with indeterminate results on HRCT (10–30 %), adjusted stratification
 Minimal disease 8 −1.65 (11.5) 0.84 12 −1.3 (7.9) 0.04
 Extensive disease 39 −2.5 (10.8) 32 −6.9 (6.9)
QILD WL
 <20 % 10 4.8 (8.6) 0.01 5 −7.6 (10.2) 0.58
 >20 % 37 −4.3 (10.6) 38 −4.7 (7.4)
QILD ZM
 <25 % 2 12.7 (3.2) 0.02 2 −13.7 (3.0) 0.08
 >25 % 45 −3.0 (10.5) 41 −4.7 (7.7)
QLF WL
<20 % 42 −1.9 (10.4) 0.63 39 −5.5 (7.9) 0.08
>20 % 5 −5.9 (14.9) 4 −1.4 (3.2)
QLF ZM
 <25 % 21 0.3 (12.3) 0.15 20 −6.0 (8.1) 0.46
 >25 % 26 −4.5 (9.1) 23 −4.2 (7.5)
  1. DLCO diffusing capacity for carbon monoxide, HRCT high-resolution computed tomography, QILD WL quantitative assessment of total extent of interstitial lung disease in whole lung, QILD ZM quantitative assessment of total extent of interstitial lung disease in zone of maximal involvement, QLF WL quantitative percentage with fibrosis in whole lung, QLF ZM quantitative percentage with fibrosis in zone of maximal involvement, SD standard deviation